Although coronary stents, glycoprotein IIb/IIIa receptor blockers, and insulin infusion appear to reduce morbidity in diabetic patients undergoing revascularization, long-term outcomes remain poorer for diabetic patients than for non-diabetic patients. Among patients with diabetes, insulin treatment is a consistent marker of worse outcomes. Randomized controlled trial results show that diabetic patients with multivessel disease have improved long-term survival with initial coronary artery bypass surgery (CABG) treatment compared with percutaneous transluminal coronary angioplasty, an effect not seen in non-diabetic patients. The advantage with CABG is apparent earlier in insulin-treated patients. This benefit with CABG may be related to a protective effect following myocardial infarction, as prior CABG greatly reduced the risk of death following spontaneous Q-wave myocardial infarction in diabetic patients (relative risk 0.09) but not in non-diabetic patients. Overall, however, the high incidence of cardiac events and poorer long-term outcomes in diabetic patients after revascularization underscore the palliative nature of these procedures in this population and the need to treat risk factors aggressively. Curr Opin Endocrinol Diabetes 2000 Diabetes , 7:184-190 © 2000 Patients with diabetes mellitus are at high risk for morbidity and mortality related to coronary artery disease (CAD). Diabetic patients have an increased incidence and severity of CAD [1], a higher risk for myocardial infarction (MI) [2,3], a higher mortality rate with coronary ischemic events [4, 5] , and a higher overall risk of death from cardiovascular causes than non-diabetic patients [2] . Because of this, diabetic patients and the physicians who care for them frequently confront the issue of coronary revascularization. Diabetic patients account for a significant percentage of the total number of patients undergoing revascularization procedures, up to 20% of the patients in some series. Accumulating evidence suggests that outcomes after coronary revascularization are different in diabetic patients than in nondiabetic patients. This article reviews coronary revascularization in diabetes patients, focusing on recent developments in the area and the implications for treatment decisions.
Percutaneous transluminal coronary angioplasty
Initial procedural success rates for revascularization with percutaneous transluminal coronary angioplasty (PTCA) are similar in diabetic and nondiabetic patients [6-8].
In-hospital complication rates are low and similar [7, 8] or slightly higher [6] in diabetic patients. Longer-term outcomes, however, have been disappointing in diabetic patients after PTCA. Survival is reduced in diabetic patients compared with non-diabetic patients, even after adjustment for differences in other baseline characteristics, and patients with diabetes have higher rates of subsequent revascularization and MI [6-8]. Diabetes is a major risk factor for restenosis of the initial PTCA site. A recent study of 2262 patients with 10 years of followup found diabetes to be the strongest predictor of target vessel revascularization [9] .
The link between restenosis and clinical outcome was examined in a French study of 485 consecutive diabetic patients undergoing balloon angioplasty without stenting [10•]. Repeat angiography was recommended for all patients at 6 months and obtained in 377 patients (83% of patients with successful initial procedures). Restenosis of the dilated segment was found in 62% of lesions, 13% with total occlusion and 49% with subtotal occlusion, which was comparable to rates seen in other studies. At least one vessel with restenosis was found in 68% of the patients (the average number of treated lesions per patient was 1.29), and 15% of patients had late target vessel occlusion. Many of these occlusions were clinically silent, with no angina in 36% and only stable angina in 33%, but the occlusions were associated with a significant decrease in ventricular function. Left ventricular ejection fraction decreased 6.2% in the group with occlusions (P = 0.0001) and was unchanged in other patients. On multivariate analysis, insulin use was an independent predictor of late vessel occlusion, whereas organ damage (retinopathy, nephropathy, neuropathy) was associated with restenosis.
Proteinuria may also be a useful marker for increased mortality risk in diabetic patients undergoing PTCA. A cohort study comparing 537 diabetic patients with available baseline urinalysis information and 2247 nondiabetic patients found significantly higher 2-year mortality rates in diabetic compared with non-diabetic patients (13.5% vs 7.3%) and, among diabetic patients, in those with dipstick macroalbuminuria compared with those without (20.3% vs 9.1%, P < 0.001) [11] . A graded increase in mortality was found with increasing amounts of proteinuria and, interestingly, no difference in survival was seen between nonproteinuric diabetic patients and non-diabetic patients.
Coronary stents
Coronary stent implantation has been shown to reduce the rate of restenosis and the need for subsequent target vessel revascularization in the general population, although their long-term value for improving outcomes such as death or MI is unclear [12] . The high rate of restenosis in diabetic patients undergoing PTCA makes these patients attractive candidates for possible benefit from the use of coronary stents. The excess risk for restenosis in diabetic patients compared with nondiabetic patients persists, however, when stents are used [13] [14] [15] . Although there are conflicting results on whether diabetes increases the risk of early stent thrombosis [16, 17] , patients with diabetes have higher rates of combined cardiac events (death, MI, and target vessel revascularization) at 1 year than do non-diabetic patients after adjustment for differences in other baseline characteristics [15, 16] .
Insulin use, again, appears to be associated with worse outcome when stents are used. In a series of 954 patients that included 16% diabetic patients on oral hypoglycemics and 10% diabetic patients on insulin, insulin use was associated with a higher in-hospital mortality rate, late cardiac events, and target lesion revascularization [17] . Cardiac event rates (death, MI, and coronary revascularization) at 1 year were 39.8% for insulin-treated diabetic patients, 30.5% for diabetic patients on oral agents, and 24.3% for non-diabetic patients. Although revascularizations accounted for the bulk of events in this study, a more recent case series of 272 patients with diabetes treated with stents found a significantly higher overall mortality rate at 13 months in insulin-treated patients as compared with diabetic patients not on insulin [18] .
Glycoprotein IIb/IIIa blockers
Platelet adherence and aggregation to abnormal surfaces is mediated by surface membrane glycoprotein receptors. A large family of drugs have been developed that block the glycoprotein IIb/IIIa receptor, and these drugs are currently undergoing intensive study as adjunctive treatment in the settings of PTCA and acute coronary syndromes. Abciximab, a monoclonal antibody fragment directed against the glycoprotein IIb/IIIa receptor, has been shown to significantly decrease non-Q-wave MI in patients undergoing urgent or elective PTCA, with or without stents [19, 20] , and to decrease the need for subsequent urgent revascularization within 30 days for patients without stents [19] .
In three large clinical trials of abciximab administered with percutaneous revascularization, 20 to 23% of the enrolled patients were classified as having a history of diabetes. Analysis of these diabetic subgroups suggests that the treatment provides similar benefits to both diabetic and non-diabetic patients. In a trial of patients undergoing urgent or elective PTCA without stents, abciximab significantly reduced non-Q-wave MI rates and the composite treatment endpoint of death or MI in both diabetic and non-diabetic patients at 6 months [21] . In a trial of PTCA with stents, the benefit of drug treatment on the primary endpoint of combined death, MI, and urgent revascularization was similar in the diabetic and nondiabetic subgroups [20] .
A recently published study pooling data from all three trials of abciximab (including a trial of PTCA for high-risk clinical situations) found an overall 1-year mortality benefit for all patients randomized to abciximab, as compared with placebo [22•]. The combined diabetic subgroups, which had a significantly higher 1 year mortality rate compared with non-diabetic subgroups (P = 0.012), also showed a mortality benefit with abciximab compared with placebo (P = 0.031), whereas the mortality benefit for non-diabetic patients did not quite reach statistical significance (P = 0.099). Non-Q-wave MI was reduced by abciximab in diabetic patients and Q-wave MI was not, similar to results in non-diabetic patients. Target vessel revascularization rates were not affected by treatment, however, suggesting that it is not likely to improve the excess long-term restenosis risk in diabetes patients.
Coronary artery bypass grafting
Patients with diabetes mellitus are also at increased risk for morbidity and mortality after coronary artery bypass grafting (CABG). The impact of diabetes on outcomes after CABG was demonstrated in a very large recently published case series of 12,198 consecutive patients undergoing surgery at Emory University Hospitals between 1978 and 1993 [23•]. The 2278 diabetic patients had higher rates of postoperative death and stroke compared with non-diabetic patients. Long-term survival was significantly decreased, with 10-year survival rates of 50% in diabetic patients versus 71% in non-diabetic patients, and diabetes was a predictor of long-term mortality in multivariate analysis. Patients with diabetes were more likely to have subsequent PTCA, but not MI or additional CABG. When the effect of diabetes treatment was examined, insulin use was a multivariate correlate of long-term mortality within the diabetic group. Insulintreated patients had significantly worse 10-year survival rates than diabetic patients not requiring insulin (43% vs 54%, P < 0.0001), even after correction for differences in baseline preoperative characteristics.
Diabetes has also been shown to be a risk factor for sternal wound infection after surgery, a complication associated with prolonged hospitalization, reoperation, and increased mortality. The results of a large prospective study, however, suggest that this risk can be sharply reduced with the use of a continuous intravenous insulin infusion to achieve tight control of perioperative blood 
Percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery: improved survival for diabetic patients with coronary artery bypass surgery
Although the outcomes for patients with diabetes are worse compared with outcomes for non-diabetic patients for both PTCA and CABG, evidence from randomized controlled trials shows that the method of revascularization has unique importance for the diabetic population. The Bypass Angioplasty Revascularization Investigation (BARI) [25] is the largest clinical trial comparing revascularization strategies, with 1829 patients including 353 (19%) diabetics. Patients with multivessel disease, angina or objective evidence of severe ischemia, and no prior revascularization procedures who required nonemergent revascularization were randomized to treatment by CABG or PTCA. Every patient had to be suitable for revascularization by either method in the judgment of an angioplasty operator and a cardiovascular surgeon. Both stable and unstable angina patients were included, with the latter predominating (64%). Diabetes was defined by treatment with oral hypoglycemic agents or insulin at study entry.
In-hospital outcomes for diabetics in BARI were similar to those in non-diabetic patients. In both groups, CABG was associated with higher rates of inhospital death or MI as compared with PTCA, and no significant difference was seen in complication rates between diabetic and non-diabetic patients within each type of procedure [25] . Longer-term follow-up, however, showed a different picture. Overall survival was worse in the diabetic patients at 5 years compared with the non-diabetic patients (73.1% vs 91.3%) [25] . (The 94 patients with a history of diabetes not requiring medications at baseline had survival equal to the patients without a history of diabetes (93.3% vs 91.1%), and were included in the analysis as non-diabetics).
Overall survival was better in diabetic patients randomized to receive CABG than in those randomized to receive PTCA (Fig. 1 ). This benefit was apparent at 5 years of follow-up (80.6% survival with CABG vs 65.5% with PTCA, P = 0.003) [8], and increased further at the recently released 7-year follow-up study (76.4% vs 55.7%, P = 0.0011) [26•].The survival advantage with CABG for diabetic patients was seen consistently across all subgroups examined, including patients with varying degrees of baseline angina severity and patients with the presence or absence of abnormal left ventricular function, double or triple vessel disease, proximal left anterior descending coronary artery disease, or class C lesions (which are technically more difficult to perform angioplasty on) [26•]. The benefit was limited to diabetic patients, however. No difference was seen in survival of non-diabetic patients by treatment after 7 years (86.4% with CABG vs 86.8% with PTCA, P = 0.72), including no treatment effect for any of the subgroups noted earlier.
The survival benefit in diabetic patients with CABG was entirely due to a decrease in cardiac mortality and was limited to the 81% of patients who received an internal mammary artery graft. At 5 years of follow-up, cardiac death was 5.8% with CABG, compared with 20.6% with PTCA [25]. Death from other causes was similar (13.3% with CABG vs 14.1% with PTCA). After 7 years, survival was 83.2% in diabetic CABG patients with IMA grafts compared with 54.5% in diabetic CABG patients with saphenous vein grafts only and 55.5% in diabetic patients with PTCA [26•]. No difference in survival rates was seen between these groups in nondiabetic patients (86.5% internal mammary artery vs 85.2% saphenous vein graft vs 86.8% PTCA at 7 years).
Among diabetic patients, the use of insulin at baseline was associated with a worse prognosis and more immediate benefit from CABG compared with the use of oral agents only. The significant treatment advantage of CABG was observed for both types of diabetic patients. However, diabetic patients using insulin who were randomized to PTCA had an excess of events occurring soon after the initial intervention, whereas those treated with oral agents showed an advantage with CABG only after several years of follow-up [27]. The 7-year survival curves for randomized BARI diabetic patients illustrate the interactions between diabetic treatments and revascularization method (Fig. 2) .
Benefit of coronary artery bypass surgery related to reduction of mortality associated with myocardial infarction
The BARI also provided important information on postrevascularization rates of MI, using rigorous methodology including annual follow-up electrocardiograms and a central electrocardiogram and MI classification laboratory to obtain data on non-fatal symptomatic Q-wave and non-Q-wave MIs, as well as silent Q-wave MIs. In randomized patients, the overall MI incidence was greater in diabetics than in non-diabetics (20.9% vs 14.0% at 5.4 years of follow-up, P = 0.004) [28] . The proportion of silent Q-wave MIs detected during routine follow-up was equivalent (21%) between the two groups, however. Postrandomization MI rates were similar between diabetic patients treated with CABG and PTCA at 5 years and non-diabetic patients [8] . The incidence of MIs during the initial hospitalization was greater with CABG, whereas MIs during follow-up were more common in the PTCA group.
A recent analysis from BARI based on all MI data, including fatal MIs determined by an independent Mortality and Morbidity Classification Committee, suggests that the benefit of CABG in diabetic patients may be significantly related to a protective effect on mortality at the time of MI [29••]. The effect of CABG and spontaneous Q-wave MI on mortality was analyzed in BARI-eligible patients, a larger group that included both randomized patients and 2010 additional eligible patients who declined randomization but agreed to be followed according to protocol. Patients who underwent CABG, either as an initial or repeat revascularization, were regarded as "CABG-protected" after their date of surgery. The spontaneous (non-procedure-related) Qwave MI rate at 5 years was 8% in diabetic patients and 4% in non-diabetic patients (relative risk in diabetics Kaplan-Meier estimates of survival for patients being treated for diabetes with insulin (heavy lines) and for patients being treated for diabetes with oral hypoglycemic drugs only (thin lines) in the Bypass Angioplasty Revascularization Investigation randomized clinical trial. The group of patients assigned to coronary artery bypass surgery is indicated by solid lines and the group assigned to percutaneous transluminal coronary angioplasty by dashed lines. CABG, coronary artery bypass surgery; I, insulin; O, oral; PTCA, percutaneous transluminal coronary angioplasty.
1.9, P < 0.001). CABG did not protect diabetic or nondiabetic patients from the occurrence of spontaneous Qwave MI. However, it did greatly protect diabetic patients from the high mortality rate associated with spontaneous Q-wave MI (80% 5-year mortality without CABG vs 17% in CABG-protected patients; relative risk, 0.09; P < 0.001), an effect not seen in non-diabetic patients. A more moderate reduction in mortality after CABG was also observed in the larger number of diabetic patients who remained free of spontaneous Qwave MI during follow-up (relative risk, 0.65; P = 0.02). The protective effect of CABG was approximately sevenfold larger after a spontaneous Q-wave MI [29••].
Generalizing from the Bypass Angioplasty Revascularization Investigation results
Three other randomized trials have compared outcomes with CABG versus PTCA. Two studies, the Emory Angioplasty Versus Surgery Trial and the Coronary Angioplasty versus Bypass Revascularization Investigation, enrolled patients with multivessel disease similar to those in BARI [30, 31] . Results in these trials were consistent with the BARI findings, with no difference in mortality between revascularization strategies in the general study population, but trends toward improved outcomes in diabetic patients with CABG. Among the 59 diabetic patients enrolled in Emory Angioplasty Versus Surgery Trial, early mortality was similar with CABG or PTCA, but recently released longer-term follow-up data showed survival curves diverging after 5 years, with improved outcome in patients treated with CABG (75.5% survival with CABG vs 60.1% with PTCA at 8 years, P = 0.23) [32•]. In Coronary Angioplasty versus Bypass Revascularization Investigation, a trend toward a higher mortality rate was seen among diabetic patients with PTCA compared with those randomized to CABG, with 10 deaths in 64 PTCA patients versus 2 deaths in 56 CABG patients after 2 years of follow-up [33] .
The Randomised Intervention Treatment of Angina (RITA-1) trial of 1011 patients in the United Kingdom examined a somewhat different study population, including a large number of patients with single vessel disease (45%). Results after 6.5 years of follow-up showed no difference in mortality with CABG versus PTCA. Among the 62 treated diabetic patients, 20 of whom had single-vessel disease, outcomes were reported as not significantly worse for those assigned CABG than for those assigned PTCA [34] . This study suggests that the benefit from CABG compared with PTCA in diabetic patients may not extend to patients with single-vessel disease.
Survival benefit in diabetic patients using CABG compared with PTCA has been more difficult to demonstrate in nonrandomized cohort studies [27, 35, 36] , raising concerns about generalizing from the results of these randomized studies. It is true that the ability to generalize from clinical trial results is limited by the studies' eligibility criteria. It is also true that comparability of treatment efficacy cannot be established from nonrandomized studies. Thus, it was not altogether surprising that the BARI-maintained registry did not entirely confirm the randomized trial results [27] , while another study supported those results [35] .
Although the BARI results suggest unequivocally that CABG should be the preferred revascularization method in diabetic patients, this is valid only for patients who meet its eligibility criteria. A study of randomly selected U.S. hospitals offering both angioplasty and bypass surgery showed that approximately 12% of patients undergoing revascularization were BARI-eligible [37] . Patients were most frequently ineligible because of single-vessel disease (34% of patients), prior procedures (18%), left main disease (8%), or lesions not appropriate for PTCA or CABG (24%, mostly unsuitable for PTCA). Thus, for 88% of patients requiring revascularization who meet these or other BARI exclusion criteria, such as diabetic patients with single-vessel disease, there are no studies to suggest that revascularization decisions should be different than in non-diabetic patients.
Conclusions
The higher incidence of cardiovascular events and the poorer long-term outcomes in diabetic patients after revascularization procedures underscore the palliative nature of revascularization in this population and the need to aggressively treat risk factors. The potential benefit of such risk factor intervention was highlighted by the Atorvastatin Versus Revascularization Treatment trial, which compared high-dose atorvostatin therapy to angioplasty in 341 patients with single-or double-vessel disease and low density lipoprotein levels greater than 115 mg/dL [38] . That study found a trend toward fewer composite cardiovascular endpoints, lower rates of bypass surgery and hospitalization for worsening angina, and a longer time to first ischemic events in the medically treated group. Similarly, a recent analysis of the Scandinavian Simvastatin Survival Study of lipid treatment in patients with known CAD found reduced rates of revascularization and coronary events in patients with impaired glucose tolerance or diabetes who had received lipid-lowering therapy [39] . It remains to be seen how much the poor prognosis of diabetic patients with CAD can be improved if diabetes and other risk factors are well controlled.
Some of the questions in the management of diabetic patients with CAD will be addressed with a new trial funded by the National Institutes of Health, the Bypass Angioplasty Revascularization Investigation (BARI) II study. This randomized multicenter clinical trial will use a 2 x 2 factorial design to examine the effects of revascularization plus aggressive medical therapy versus aggressive medical therapy alone, as well as insulinproviding versus insulin-sensitizing strategies for tight glycemic control (Hgb A1c < 7.0%). A total of 2600 diabetic patients with CAD (at least one stenosis > 50%), stable angina or documented ischemia, and suitability for revascularization by at least one method will be enrolled. The revascularization technique will be chosen by individual physicians, with the goal of minimizing or eliminating CAD symptoms and ischemia. The insulin-sensitizing treatment arm will use metformin and thiazolidinediones approved by the Food and Drug Administration, while the insulinproviding treatment arm will use sulfonylurea drugs, repaglinide, and insulin itself. The primary outcome will be 5-year all-cause mortality, with secondary endpoints including cardiac mortality, MI, angina, and quality of life. This study suggests that the survival benefit seen with CABG in diabetic patients may be significantly related to an improvement in subsequent mortality with MI. Among patients with multivessel disease eligible for the BARI trial, diabetic patients had significantly higher rates of death and spontaneous Qwave MI at 5 years than non-diabetic patients. Prior CABG (as initial revascularization or subsequent procedure) dramatically reduced the high mortality rate following spontaneous Q-wave MI in diabetic patients (relative risk, 0.09; P < 0.001) but not in non-diabetic patients (P = 0.26). A smaller protective effect of CABG on mortality was also seen in diabetic patients who did not have spontaneous Qwave MI (relative risk, 0.65).
